You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLeuprolide
Accession NumberDB00007  (BTD00009, BIOD00009)
TypeBiotech
GroupsApproved, Investigational
DescriptionLeuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.
Protein structureDb00007
Related Articles
Protein chemical formulaC59H84N16O12
Protein average weight1209.3983 Da
Sequences
>Leuprolide
PHWSYLLR
Download FASTA Format
Synonyms
(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone
L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
Leuprorelin
Leuprorelina
Leuproreline
Leuprorelinum
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2002-05-15Not applicableUs
EligardkitSanofi Aventis U.S. Llc2002-01-23Not applicableUs
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2002-08-26Not applicableUs
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2005-01-07Not applicableUs
EligardkitSanofi Aventis U.S. Llc2002-01-23Not applicableUs
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2002-08-26Not applicableUs
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2005-01-07Not applicableUs
EligardkitSanofi Aventis U.S. Llc2002-01-23Not applicableUs
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2003-02-26Not applicableUs
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2002-05-15Not applicableUs
EligardkitSanofi Aventis U.S. Llc2002-01-23Not applicableUs
EligardkitsubcutaneousTolmar Pharmaceuticals Inc.2003-02-26Not applicableUs
Eligard 22.5mgpowder for suspension, sustained-release28.2 mgsubcutaneousSanofi Aventis Canada Inc2003-12-01Not applicableCanada
Eligard 30 mgpowder for suspension, sustained-release35.8 mgsubcutaneousSanofi Aventis Canada Inc2004-04-29Not applicableCanada
Eligard 45 mgpowder for suspension, sustained-release58.2 mgsubcutaneousSanofi Aventis Canada Inc2005-08-15Not applicableCanada
Eligard 7.5mgpowder for suspension, sustained-release10.2 mgsubcutaneousSanofi Aventis Canada Inc2003-12-01Not applicableCanada
Leuprolide Acetate Injectionliquid5 mgsubcutaneousNovopharm LimitedNot applicableNot applicableCanada
Lupronliquid5 mgsubcutaneousAbbvie Corporation1985-12-31Not applicableCanada
Lupron DepotkitAbb Vie Inc.1995-12-22Not applicableUs
Lupron Depotpowder for suspension, sustained-release15 mgintramuscularAbbvie CorporationNot applicableNot applicableCanada
Lupron Depotpowder for suspension, sustained-release30 mgintramuscularAbbvie Corporation1999-09-13Not applicableCanada
Lupron DepotkitAbb Vie Inc.1995-12-22Not applicableUs
Lupron DepotkitAbb Vie Inc.1995-12-22Not applicableUs
Lupron Depotpowder for suspension, sustained-release7.5 mgintramuscularAbbvie Corporation1989-12-31Not applicableCanada
Lupron Depotpowder for suspension, sustained-release11.25 mgintramuscularAbbvie Corporation1999-09-13Not applicableCanada
Lupron DepotkitAbb Vie Inc.2010-11-08Not applicableUs
Lupron DepotkitAbb Vie Inc.1990-10-22Not applicableUs
Lupron Depotpowder for suspension, sustained-release3.75 mgintramuscularAbbvie Corporation1992-12-31Not applicableCanada
Lupron Depotpowder for suspension, sustained-release11.25 mgintramuscularAbbvie CorporationNot applicableNot applicableCanada
Lupron DepotkitAbb Vie Inc.1989-01-26Not applicableUs
Lupron Depotpowder for suspension, sustained-release22.5 mgintramuscularAbbvie Corporation1997-01-29Not applicableCanada
Lupron Depot-pedkitAbb Vie Inc.1993-04-16Not applicableUs
Lupron Depot-pedkitAbb Vie Inc.1993-04-16Not applicableUs
Lupron Depot-pedkitAbb Vie Inc.1993-04-16Not applicableUs
Lupron Depot-pedkitAbb Vie Inc.1993-04-16Not applicableUs
Lupron Depot-pedkitAbb Vie Inc.1993-04-16Not applicableUs
Lupron Depot-pedkitREMEDYREPACK INC.2015-07-28Not applicableUs
Zeulide Depotpowder for suspension, sustained-release; kit5.06 mgintramuscularPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Leuprolide Acetateinjection, solution1 mg/.2mLsubcutaneousEon Labs, Inc.1998-08-04Not applicableUs
Leuprolide AcetatekitSun Pharma Global FZE2014-12-15Not applicableUs
Leuprolide AcetatekitTeva Parenteral Medicines, Inc.2000-11-06Not applicableUs
Leuprolide AcetatekitSandoz Inc1998-08-04Not applicableUs
Leuprolide AcetatekitsubcutaneousSun Pharma Global Inc.2009-03-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EnantoneNot Available
LeuplinTakeda
LeuProMaxxBaxter/Teva
LeupromerNot Available
LutrateNot Available
MemryteCuraxis
Prostap 3Takeda UK
Prostap SRTakeda UK
ViadurBayer AG
Brand mixtures
NameLabellerIngredients
Lupaneta PackAbb Vie Inc.
Salts
Name/CASStructureProperties
Leuprolide acetate
74381-53-6
Thumb
  • InChI Key: RGLRXNKKBLIBQS-XNHQSDQCSA-N
  • Monoisotopic Mass: 1268.666591604
  • Average Mass: 1269.4502
DBSALT000105
Categories
UNIIEFY6W0M8TG
CAS number53714-56-0
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty
PharmacodynamicsUsed in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.
Mechanism of actionLeuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
Related Articles
AbsorptionBioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of distribution
  • 27 L [intravenous bolus administration to healthy male volunteers]
Protein binding43% to 49%
Metabolism

Primarily degraded by peptidase and not by cytochrome P450 enzymes.

Route of eliminationExcretion in urine
Half life~3 hours
Clearance
  • 8.34 L/h [healthy male receiving a 1-mg IV bolus]
ToxicityIn rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit
Powder for suspension, sustained-releasesubcutaneous28.2 mg
Powder for suspension, sustained-releasesubcutaneous35.8 mg
Powder for suspension, sustained-releasesubcutaneous58.2 mg
Powder for suspension, sustained-releasesubcutaneous10.2 mg
Injection, solutionsubcutaneous1 mg/.2mL
Kitsubcutaneous
Kit
Liquidsubcutaneous5 mg
Powder for suspension, sustained-releaseintramuscular11.25 mg
Powder for suspension, sustained-releaseintramuscular15 mg
Powder for suspension, sustained-releaseintramuscular22.5 mg
Powder for suspension, sustained-releaseintramuscular3.75 mg
Powder for suspension, sustained-releaseintramuscular30 mg
Powder for suspension, sustained-releaseintramuscular7.5 mg
Powder for suspension, sustained-release; kitintramuscular5.06 mg
Prices
Unit descriptionCostUnit
Eligard 45 mg syringe2959.2USD syringe
Eligard 30 mg syringe1972.8USD syringe
Eligard 22.5 mg syringe1479.6USD syringe
Lupron 2-wk 1 mg/0.2 ml kit594.37USD kit
Eligard 7.5 mg syringe493.2USD syringe
Leuprolide Acetate 1 mg/0.2ml Kit 2.8ml 2-Week Kit400.74USD box
Leuprolide 2wk 1 mg/0.2 ml kit385.33USD kit
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5728396 No1997-01-302017-01-30Us
US5932547 No1997-06-132017-06-13Us
US5985305 No1997-01-302017-01-30Us
US6036976 No1996-12-132016-12-13Us
US6113938 No1998-07-242018-07-24Us
US6124261 No1997-06-132017-06-13Us
US6132420 No1997-01-302017-01-30Us
US6156331 No1997-01-302017-01-30Us
US6235712 No1997-06-132017-06-13Us
US6375978 No1998-12-172018-12-17Us
US6395292 No1997-01-302017-01-30Us
US6565874 No1998-10-282018-10-28Us
US6626870 No2000-03-272020-03-27Us
US6773714 No1998-10-282018-10-28Us
US7429559 No1999-01-132019-01-13Us
US8815801 No2002-06-282022-06-28Us
US8921326 No2011-02-052031-02-05Us
US9283282 No1998-10-282018-10-28Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
hydrophobicity0.1Not Available
References
Synthesis Reference

Daniel Kadzimirzs, Gerhard Jas, Volker Autze, “Solution-Phase Synthesis of Leuprolide and Its Intermediates.” U.S. Patent US20090005535, issued January 01, 2009.

US20090005535
General References
  1. Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8. [PubMed:15568711 ]
  2. Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54. [PubMed:15780490 ]
  3. Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10. [PubMed:16370917 ]
  4. Link [Link]
  5. RxMed [Link]
External Links
ATC CodesL02AE02
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (477 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Leuprolide.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Leuprolide.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Leuprolide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.
AmantadineAmantadine may increase the QTc-prolonging activities of Leuprolide.
AmiodaroneLeuprolide may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Leuprolide.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Leuprolide.
AnagrelideLeuprolide may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Leuprolide.
ArformoterolArformoterol may increase the QTc-prolonging activities of Leuprolide.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Leuprolide.
Arsenic trioxideLeuprolide may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherLeuprolide may increase the QTc-prolonging activities of Artemether.
AsenapineLeuprolide may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Leuprolide.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Leuprolide.
AzithromycinLeuprolide may increase the QTc-prolonging activities of Azithromycin.
BedaquilineLeuprolide may increase the QTc-prolonging activities of Bedaquiline.
BevacizumabBevacizumab may increase the cardiotoxic activities of Leuprolide.
BortezomibBortezomib may increase the QTc-prolonging activities of Leuprolide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Leuprolide.
BuserelinBuserelin may increase the QTc-prolonging activities of Leuprolide.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leuprolide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Leuprolide.
CeritinibLeuprolide may increase the QTc-prolonging activities of Ceritinib.
ChloroquineLeuprolide may increase the QTc-prolonging activities of Chloroquine.
ChlorpromazineLeuprolide may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Leuprolide.
CiprofloxacinLeuprolide may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideLeuprolide may increase the QTc-prolonging activities of Cisapride.
CitalopramLeuprolide may increase the QTc-prolonging activities of Citalopram.
ClarithromycinLeuprolide may increase the QTc-prolonging activities of Clarithromycin.
ClomipramineClomipramine may increase the QTc-prolonging activities of Leuprolide.
ClozapineLeuprolide may increase the QTc-prolonging activities of Clozapine.
CrizotinibLeuprolide may increase the QTc-prolonging activities of Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Leuprolide.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Leuprolide.
DasatinibDasatinib may increase the QTc-prolonging activities of Leuprolide.
DegarelixDegarelix may increase the QTc-prolonging activities of Leuprolide.
DesfluraneDesflurane may increase the QTc-prolonging activities of Leuprolide.
DesipramineDesipramine may increase the QTc-prolonging activities of Leuprolide.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Leuprolide.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Leuprolide.
DigoxinDigoxin may decrease the cardiotoxic activities of Leuprolide.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Leuprolide.
DisopyramideLeuprolide may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.
DofetilideLeuprolide may increase the QTc-prolonging activities of Dofetilide.
DolasetronLeuprolide may increase the QTc-prolonging activities of Dolasetron.
DomperidoneLeuprolide may increase the QTc-prolonging activities of Domperidone.
DoxepinDoxepin may increase the QTc-prolonging activities of Leuprolide.
DronedaroneLeuprolide may increase the QTc-prolonging activities of Dronedarone.
DroperidolLeuprolide may increase the QTc-prolonging activities of Droperidol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.
EliglustatLeuprolide may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.
EribulinEribulin may increase the QTc-prolonging activities of Leuprolide.
ErythromycinLeuprolide may increase the QTc-prolonging activities of Erythromycin.
EscitalopramLeuprolide may increase the QTc-prolonging activities of Escitalopram.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide.
EzogabineEzogabine may increase the QTc-prolonging activities of Leuprolide.
FamotidineFamotidine may increase the QTc-prolonging activities of Leuprolide.
FelbamateFelbamate may increase the QTc-prolonging activities of Leuprolide.
FingolimodFingolimod may increase the QTc-prolonging activities of Leuprolide.
FlecainideLeuprolide may increase the QTc-prolonging activities of Flecainide.
FluconazoleFluconazole may increase the QTc-prolonging activities of Leuprolide.
FluoxetineLeuprolide may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolLeuprolide may increase the QTc-prolonging activities of Flupentixol.
FormoterolFormoterol may increase the QTc-prolonging activities of Leuprolide.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Leuprolide.
Gadobenic acidLeuprolide may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Leuprolide.
GemifloxacinLeuprolide may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Leuprolide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.
GoserelinLeuprolide may increase the QTc-prolonging activities of Goserelin.
GranisetronLeuprolide may increase the QTc-prolonging activities of Granisetron.
HaloperidolLeuprolide may increase the QTc-prolonging activities of Haloperidol.
HistrelinHistrelin may increase the QTc-prolonging activities of Leuprolide.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Leuprolide.
IbandronateIbandronate may increase the QTc-prolonging activities of Leuprolide.
IbutilideLeuprolide may increase the QTc-prolonging activities of Ibutilide.
IloperidoneLeuprolide may increase the QTc-prolonging activities of Iloperidone.
ImipramineImipramine may increase the QTc-prolonging activities of Leuprolide.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Leuprolide.
IndapamideIndapamide may increase the QTc-prolonging activities of Leuprolide.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Leuprolide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Leuprolide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Leuprolide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Leuprolide.
IsradipineIsradipine may increase the QTc-prolonging activities of Leuprolide.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Leuprolide.
IvabradineIvabradine may increase the QTc-prolonging activities of Leuprolide.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Leuprolide.
LapatinibLapatinib may increase the QTc-prolonging activities of Leuprolide.
LenvatinibLeuprolide may increase the QTc-prolonging activities of Lenvatinib.
LevofloxacinLeuprolide may increase the QTc-prolonging activities of Levofloxacin.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide.
LithiumLithium may increase the QTc-prolonging activities of Leuprolide.
LopinavirLeuprolide may increase the QTc-prolonging activities of Lopinavir.
LumefantrineLeuprolide may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Leuprolide.
MefloquineMefloquine may increase the QTc-prolonging activities of Leuprolide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.
MethadoneLeuprolide may increase the QTc-prolonging activities of Methadone.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Leuprolide.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Leuprolide.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Leuprolide.
MifepristoneMifepristone may increase the QTc-prolonging activities of Leuprolide.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Leuprolide.
MirabegronMirabegron may increase the QTc-prolonging activities of Leuprolide.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Leuprolide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Leuprolide.
MoexiprilMoexipril may increase the QTc-prolonging activities of Leuprolide.
MoxifloxacinLeuprolide may increase the QTc-prolonging activities of Moxifloxacin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Leuprolide.
NicardipineNicardipine may increase the QTc-prolonging activities of Leuprolide.
NilotinibLeuprolide may increase the QTc-prolonging activities of Nilotinib.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Leuprolide.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Leuprolide.
OctreotideOctreotide may increase the QTc-prolonging activities of Leuprolide.
OfloxacinLeuprolide may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Leuprolide.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Leuprolide.
OndansetronLeuprolide may increase the QTc-prolonging activities of Ondansetron.
OuabainOuabain may decrease the cardiotoxic activities of Leuprolide.
OxytocinOxytocin may increase the QTc-prolonging activities of Leuprolide.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Leuprolide.
PaliperidoneLeuprolide may increase the QTc-prolonging activities of Paliperidone.
PanobinostatLeuprolide may increase the QTc-prolonging activities of Panobinostat.
ParoxetineParoxetine may increase the QTc-prolonging activities of Leuprolide.
PasireotidePasireotide may increase the QTc-prolonging activities of Leuprolide.
PazopanibLeuprolide may increase the QTc-prolonging activities of Pazopanib.
PentamidineLeuprolide may increase the QTc-prolonging activities of Pentamidine.
PerflutrenLeuprolide may increase the QTc-prolonging activities of Perflutren.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide.
PimozideLeuprolide may increase the QTc-prolonging activities of Pimozide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Leuprolide.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide.
PrimaquineLeuprolide may increase the QTc-prolonging activities of Primaquine.
ProcainamideLeuprolide may increase the QTc-prolonging activities of Procainamide.
PromazineLeuprolide may increase the QTc-prolonging activities of Promazine.
PromethazinePromethazine may increase the QTc-prolonging activities of Leuprolide.
PropafenoneLeuprolide may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Leuprolide.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Leuprolide.
QuetiapineLeuprolide may increase the QTc-prolonging activities of Quetiapine.
QuinidineLeuprolide may increase the QTc-prolonging activities of Quinidine.
QuinineLeuprolide may increase the QTc-prolonging activities of Quinine.
RanolazineRanolazine may increase the QTc-prolonging activities of Leuprolide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Leuprolide.
RisperidoneRisperidone may increase the QTc-prolonging activities of Leuprolide.
RitonavirRitonavir may increase the QTc-prolonging activities of Leuprolide.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Leuprolide.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Leuprolide.
SaquinavirLeuprolide may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide.
SertralineSertraline may increase the QTc-prolonging activities of Leuprolide.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Leuprolide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Leuprolide.
SorafenibSorafenib may increase the QTc-prolonging activities of Leuprolide.
SotalolLeuprolide may increase the QTc-prolonging activities of Sotalol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Leuprolide.
SulfisoxazoleLeuprolide may increase the QTc-prolonging activities of Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Leuprolide.
SunitinibSunitinib may increase the QTc-prolonging activities of Leuprolide.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Leuprolide.
TelavancinLeuprolide may increase the QTc-prolonging activities of Telavancin.
TelithromycinLeuprolide may increase the QTc-prolonging activities of Telithromycin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Leuprolide.
TetrabenazineLeuprolide may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineLeuprolide may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Leuprolide.
TizanidineTizanidine may increase the QTc-prolonging activities of Leuprolide.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.
TolterodineTolterodine may increase the QTc-prolonging activities of Leuprolide.
ToremifeneLeuprolide may increase the QTc-prolonging activities of Toremifene.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Leuprolide.
TrazodoneTrazodone may increase the QTc-prolonging activities of Leuprolide.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Leuprolide.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Leuprolide.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Leuprolide.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Leuprolide.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide.
VandetanibLeuprolide may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Leuprolide.
VemurafenibLeuprolide may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Leuprolide.
VilanterolVilanterol may increase the QTc-prolonging activities of Leuprolide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Leuprolide.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Leuprolide.
VorinostatVorinostat may increase the QTc-prolonging activities of Leuprolide.
ZiprasidoneLeuprolide may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolLeuprolide may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Peptide binding
Specific Function:
Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.
Gene Name:
GNRHR
Uniprot ID:
P30968
Molecular Weight:
37730.355 Da
References
  1. Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. [PubMed:16809153 ]
  2. Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43. [PubMed:10687850 ]
  3. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100. [PubMed:9625809 ]
  4. Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7. [PubMed:15758569 ]
  5. Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92. [PubMed:10394541 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:59